Taxane therapy for early stage breast cancer

Women's Health

Volumn 2, Issue 1, 2006, Pages 99-114

  Nabholtz, Jean Marc ^a   Gligorov, Joseph ^b  

^a Breast Cancer Research Institute   (France)

^b HÔPITAL TENON   (France)

Author keywords

Adjuvant; Anthracyclines; Breast cancer; Docetaxel; Neoadjuvant; Paclitaxel; Taxanes

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ADVANCED CANCER; ANEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG ISOLATION; DRUG SAFETY; DRUG SYNTHESIS; EARLY CANCER; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; METASTASIS; MONOTHERAPY; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 33646762011     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.1.99     Document Type: Review

References (67)

1. Greenlee RT, Hill-Harmon MB, Murray Y et al.: Cancer statistics, 2001. CA Cancer J. Clin. 51, 15-36 (2001).
2. Crown J: Evolution in the treatment of advanced breast cancer. Semin. Oncol. 25(Suppl. 12), 12-17 (1998).
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352, 930-942 (1998).
4. Wani MC, Taylor HL, Wall ME, Coggon P, Mcphail AT: Plant antitumour agents VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325-2327 (1971).
5. Rowinsky EK, Donehower RC: Drug therapy: paclitaxel (Taxol). N. Engl. J. Med. 332, 1004-1014 (1995).
6. Lavelle F, Gueritte-Voegelein F, Guenard D: Le taxotere: des aiguilles d'if a la clinique. Bull. Cancer 80, 326-338 (1993).
7. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl. 2), 3-8(2004).
8. Nabholtz JM, Tonkin K, Smylie M et al.: Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expen Opin. Pharmacother. 1, 187-206 (2000).
9. Nabholtz J-M, Gelmon K, Bontenbal M et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 14, 1858-1867 (1996).
10. Peretz T, Sulkes A. Chollet P et al.: A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur. J. Cancer 31(Suppl.5), S75a (1995).
11. Winer EP, Berry DA, Woolf S et al.: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. Clin. Oncol. 22, 2061-2068 (2004).
12. Smith RE, Brown AM, Mamounas EP et al.: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol. 17, 3403-3411 (1999).
13. Holmes FA, Valero, V, Buzdar AU et al.: Final results: randomized Phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patient (pt) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 17, 110a (1998).
14. Paridaens R, Biganzoli L, Bruning P et al.: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J. Clin. Oncol. 18, 724-733 (2000).
15. Sledge GW, Neuberg D, Bernardo P et al.: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. 21, 588-592 (2003).
16. Bishop J, Dewar J, Toner G et al.: Initial paclitaxel improves outcome compared with cmfp combination chemotherapy as frontline therapy in untreated metastatic breast cancer. J. Clin. Oncol. 17, 2355-2364 (1999).
17. Perez EA, Vogel CL, Irwin DH et al.: Multicenter Phase II trial of weekly paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. 19, 4216-4223 (2001).
18. Green MC, Buzdar AU, Smith T et al.: Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC-final results of a prospective Phase III randomized trial. Proc. Am. Soc. Clin. Oncol. 21, 35a (2002).
19. Seidman AD, Berry D, Cirrincione C et al.: CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc. Am. Soc. Clin. Oncol. 22, 512a (2004).
20. Gianni L, Vigano, L, Locatelli A et al.: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol. 15, 1906-1915 (1997).
21. Gianni L, Munzone E, Capri G et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicine in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-sequence-finding study. J. Clin. Oncol. 13, 2688-2699 (1995).
22. Jassem J, Pienkowski T, Pluzanska A et al.: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphomide as first-line therapy for women with metastatic breast cancer: results of a randomized Phase III multicenter trial. J. Clin. Oncol. 19. 1707-1715. (2001).
23. Biganzoli L, Cufer T, Bruning P et al.: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter Phase III trial. J. Clin. Oncol. 20, 3114-3121 (2002).
24. Luck HJ, Thomssen C, Untch M et al.: Multicentric Phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs. epirubicin/cyclophosphamide (EC. A study of the AGO Breast Cancer Group. Proc. Am. Soc. Clin. Oncol. 19, 280a (2000).
25. Carmichael J: UKCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and Taxol (ET) in the first tine treatment of women with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 20, 22a (2001) (Abstract 84).
26. Gianni L, Baselga J, Eiermann W et al.: European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). Proc. Am. Soc. Clin. Oncol. 24, 513a (1999).
27. Chan S, Friedrichs K, Noel D et al.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 17(8), 2341-2354 (2005).
28. Nabholtz J-M, Senn HJ, Bezwoda WR et al.: Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J. Clin. Oncol. 17(5), 1413-1424 (1999).
29. Sjostrom J, Blomqvist C, Mouridsen H et al.: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randornised Phase III study with crossover on progression by the Scandinavian Breast Group. Eur. J. Cancer 35(8), 1194-1201 (1999).
30. Bonneterre J, Roche H, Monnier A et al.: Docetaxel vs. 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br. J. Cancer 87(11), 1210-1215 (2002).
31. Ravdin P, Erban J, Overmoyer B et al.: Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur. J. Cancer Suppl. 1, S201 (2003) (Abstract 670).
32. Loffler TM: Is there a place for 'dosedense' weekly schedules of the taxoids? Semin. Oncol. 25(Suppl. 12), 32-34 (1998).
33. Nabholtz JM: Docetaxel (taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin. Oncol. 26(Suppl, 9), 7-13 (1999).
34. Rudek MA, Sparreboom A, Garrett-Mayer ES et al.: Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur. J. Cancer 40, 1170-1178 (2004).
35. Nabholtz JM, Falkson C, Campos D et al.: Docetaxel and doxorubicin (AT) compared to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J. Clin. Oncol. 21, 968-975 (2003).
36. Nabholtz J, Paterson A, Dirix L et al.: A Phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 20, 22a (2001).
37. Mackey JR, Paterson A, Dirix LY et al.: Final results of the Phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 21. 35a (2002).
38. Bontenbal M, Braun JJ, Creemers GJ et al.: Phase III study comparing AT (adriamycin, docetaxel) to FAC (fluorouracil, adriamycin, cyclophospbamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur. J. Cancer 1, S201 (2003) (Abstract 671).
39. Bonneterre J, Dieras V, Tubiana-Hulin M et al.: Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br. J. Cancer 91, 1466-1471 (2004).
40. Henderson IC, Berry DA; Demetri GD et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976-983 (2003).
41. Mamounas E, Bryant J, Lembersky B et al.: Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc. Am. Soc. Clin. Oncol. 22, 12a (2003).
42. Albain KS, Green SJ, Ravdin PM et al.: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc. Am. Soc. Clin. Oncol. 21, 143A (2002).
43. Citron ML, Berry DA, Cirrincione C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439 (2003). Erratum in: J. Clin. Oncol. 21, 2226 (2003).
44. Fisher B, Anderson S, Wickerham DL et al.: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J. Clin. Oncol. 15, 1858-1869 (1997).
45. Fisher B, Anderson S, Decillis A et al.: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from the national surgical adjuvant breast and bowel project B-25. J. Clin. Oncol. 17, 3374-3388 (1999).
46. Green M, Buzdar A, Smith T et al.: Weekly paclitaxel (P) followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3 week (Q 3 wk) P therapy followed by FAC - final results of a prospective Phase III randomized trial. Proc. Am. Soc. Clin. Oncol. 21, 135a (2002).
47. Gasparini G: Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2, 733-740 (2001).
48. Buzdar AU, Singletary SE, Valero V et al.: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin. Cancer Res. 8, 1073-1079 (2002).
49. Loesch D, Greco FA, O'Shaugnessy J et al.: A randomized, multicenter Phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. Breast Cancer Res. Treat. 88(Suppl. 1), 28a (2004).
50. Nabholtz J-M, Pienkowsi T, Mackey J et al.: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclopbosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Procc. Am. Soc. Clin. Oncol. 21, 141a (2002).
51. Martin M, Pienkowski T, Mackey J et al.: TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res. Treat. 82, 43a (2003).
52. Nabholtz JM, Cantin J, Chang J et al.: Phase III trial comparing granulocyte colony-stimulating factor (G-CSF) to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophospamide (TAC): results of the BCIRG 004 trial. Clin. Breast Cancer 3(4), 268-275 (2002).
53. Roche H, Fumoleau P, Spielmann M et al.: Five years analysis of the PACS 01 trial: 6 cycles of FEC 100 vs. 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res. Treat. 83, 27a (2004).
54. Goldstein L, O'Neill A, Sparano J et al.: E2197: Phase III AT (doxorubucin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 512).
55. Kaufmann M, Von Minckwitz G, Smith R et al.: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J. Clin. Oncol. 21(13), 2600-2608 (2003). Erratum in: J. Clin. Oncol. 21, 4469 (2003).
56. Wolmark N, Wang J, Mamounas E et al.: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl Cancer Inst. Monogr. 30, 96-102 (2001).
57. Buzdar AU, Singletary SE, Theriault RL et al.: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J. Clin. Oncol. 17, 3412-3417 (1999).
58. Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 11 (Suppl. 8), 5-18 (1997).
59. Amat S, Bougnoux P, Penaul-Liorca F et al.: Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br. J. Cancer 88, 1339-1345 (2003).
60. Estevez LG, Cuevas JM, Anton A et al.: Weekly docetaxel is effective as neoadjuvant chemotherapy for stage II and III breast cancer. Efficacy and correlation with biological markers in a Phase II, multicenter study. Clin. Cancer Res. 9, 686-692 (2003).
61. Dieras V, Fumoleau P, Romieu G et al.: Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J. Clin. Oncol. 22, 4958-4965 (2004).
62. Evans TR, Yellowlees A, Foster E et al.: Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J. Clin. Oncol. 23, 2988-2995 (2005).
63. Luporsi L, Vanlemmens L, Coudert B et al.: Six cycles of FEC 100 vs. 6 cycles of epirubicin-docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: preliminary results of a randomized Phase II trial of Girec S01. Proc. Am. Soc. Clin. Oncol. 19, 92a (2000).
64. Bear HD, Anderson S, Smith RE et al.: A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res. Treat. 88(Suppl. 1), 26a (2004).
65. Smith IC, Heys SD, Hutcheon AW et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol. 20, 1456-1466 (200).
66. Von Minckwitz G, Raab G, Caputo A et al.: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J. Clin. Oncol. 23, 2676-2685 (2005).
67. Slamon D, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).